U.S. Markets closed

Cempra (CEMP) Catches Eye: Stock Rises 9.7%

Zacks Equity Research

Cempra, Inc. (CEMP) was a big mover last session with its shares rising nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company, as the stock has lost over 12% in the past one-month time frame.

This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cempra currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Better-ranked Med-Drug stocks include Lannett Company, Inc. (LCI), Endocyte, Inc. (ECYT) and BioCryst Pharmaceuticals, Inc. (BCRX). While LCI and ECYT sport a Zacks Rank #1 (Strong Buy), BCRX carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

CEMPRA INC (CEMP): Free Stock Analysis Report

LANNETT COMP (LCI): Free Stock Analysis Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report


Zacks Investment Research